QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ALMS

QT44Alumis Inc. Common Stock
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
23.41
+0.36+1.56%
OverviewShort InterestFilings
ALMSQT44Alumis Inc. Common Stock·NASDAQ
OverviewShort InterestFilings
23.41+1.56%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.92
Insider Own30.83%
Shs Outstand127.49M
Perf Week12.01%
Market Cap2.85BForward P/E-EPS next Y-2.73Insider Trans1.47%Shs Float-Perf Month8.73%
Enterprise Value2.82BPEG-EPS next Q-0.70Inst Own-Short Float-Perf Quarter-7.76%
Income-234437003.00P/S338.62EPS this Y-48.77%Inst Trans-Short Ratio-Perf Half Y105.35%
Sales8.40MP/B5.08EPS next Y4.28%ROA-35.35%Short Interest-Perf YTD139.86%
Book/sh4.45P/C-EPS next 5Y-ROE-54.63%52W High30.60 -23.50%Perf Year677.74%
Cash/sh4.10P/FCF-EPS past 3/5Y-ROIC-71.89%52W Low2.76 748.19%Perf 3Y-
Dividend Est.-EV/EBITDA-6.80Sales past 3/5Y-Gross Margin89.63%Volatility5.17% 4.32%Perf 5Y-
Dividend TTM-EV/Sales335.26EPS Y/Y TTM62.24%Oper. Margin-5364.02%ATR (14)1.51Perf 10Y-
Dividend Ex-Date-Quick Ratio7.51Sales Y/Y TTM-Profit Margin-2825.70%RSI (14)56.76Recom2.14
Dividend Gr. 3/5Y-Current Ratio7.51EPS Q/Q59.34%SMA209.74%Beta1.50Target Price39.33
Payout0.00%Debt/Eq0.06Sales Q/Q-88.24%SMA501.89%Rel Volume1.66Prev Close23.05
Employees168LT Debt/Eq0.11EarningsAug 12SMA20041.09%Avg Volume1.14MPrice23.41
IPO DateFeb 22, 2021Option/ShortYes / YesEPS/Sales Surpr.0.37% 0.00%Net Debt/EBITDA0.07Volume1,883,049Change1.56%
Analyst Ratings
DateActionAnalystRatingTarget
May-19-26ReiteratedChardan CapitalBuy$37 → $40
May-15-26ReiteratedMorgan StanleyOverweight$38 → $39
May-15-26ReiteratedH.C. Wainwright$40 → $25
May-15-26DowngradeHC Wainwright & Co.Buy → Neutral
May-15-26ReiteratedWells FargoOverweight$39 → $51
May-15-26ReiteratedGuggenheimBuy$32 → $34
Mar-10-26ReiteratedRaymond James$46
Jan-21-26InitiatedChardanBuy$37
Jan-21-26ReiteratedLoop Capital Markets$37
Jan-09-26ReiteratedH.C. Wainwright$20 → $40
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue9240
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A133
Gross Profit821-3
Selling, General and Administrative Excl. Other769235
Research and Development371386266
Other Operating Expense10-30-3
Operating Income-450-427-301
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-34-175-7
Net Income Before Taxes-246-252-294
Income Taxes-9-90
Consolidated Net Income-238-243-294
Net Income From Continuing Operations-238-243-294
Net Income-238-243-294
EPS (Recurring)-1.91-2.32-10.38
EPS (Basic, Before Extraordinaries)-1.91-2.32-10.38
EPS (Diluted)-1.92-2.32-10.38
EBITDA-414-248-291
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio325.14345.67—
Gross Margin88.8987.50—
Operating Margin-5,000.00-1,779.17—
Net Margin-2,644.44-1,012.50—
Shares Outstanding12585028
Market Capitalization2,9268,296—
Operating Lease Expense
———
Insider Trading Volume
$24.53$22.47$20.42$18.37$16.31● Close Price0.00M7.75M15.50M23.25M31.00MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Drappa JornChief Medical OfficerMay 22 '26Option Exercise6.6553,704357,298164,465May 27 12:00 AM
AKKARAJU SRINIVASDirectorJan 09 '26Buy17.00588,2359,999,9951,853,488Jan 13 12:00 AM
Foresite Labs, LLC10% OwnerJan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12 12:00 AM
Foresite Capital Management VI LLC10% OwnerJan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12 12:00 AM
Tananbaum James B.director, 10 percent owner:Jan 08 '26Buy17.00411,7646,999,9885,702,536Jan 12 12:00 AM
AKKARAJU SRINIVASDirectorDec 05 '25Buy9.84186,3771,833,7601,265,253Dec 09 12:00 AM
AKKARAJU SRINIVASDirectorDec 04 '25Buy8.1866,027540,1011,078,876Dec 04 12:00 AM
AKKARAJU SRINIVASDirectorDec 03 '25Buy7.75100,000775,0001,012,849Dec 04 12:00 AM
AKKARAJU SRINIVASDirectorDec 02 '25Buy7.5596,000724,800912,849Dec 04 12:00 AM
AKKARAJU SRINIVASDirectorDec 01 '25Buy7.4686,350644,171816,849Dec 01 12:00 AM
AKKARAJU SRINIVASDirectorNov 28 '25Buy7.6438,702295,683730,499Dec 01 12:00 AM
AKKARAJU SRINIVASDirectorNov 26 '25Buy7.6448,537370,823691,797Dec 01 12:00 AM
Foresite Capital Management VI LLC10% OwnerNov 21 '25Buy7.3872,212532,9252,614,215Nov 25 12:00 AM
Tananbaum James B.director, 10 percent owner:Nov 21 '25Buy7.3872,212532,9252,614,215Nov 25 12:00 AM
Foresite Labs, LLC10% OwnerNov 21 '25Buy7.3872,212532,9252,614,215Nov 25 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR